Myriad Genetics (NASDAQ:MYGN) Updates FY 2025 Earnings Guidance

Myriad Genetics (NASDAQ:MYGN) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of 0.070-0.110 for the period, compared to the consensus EPS estimate of 0.090. The company issued revenue guidance of $840.0 million-$860.0 million, compared to the consensus revenue estimate of $883.1 million. Myriad Genetics also updated its FY25 guidance to $0.07-0.11 EPS.

Myriad Genetics Price Performance

Shares of MYGN opened at $13.68 on Wednesday. The stock has a fifty day moving average price of $15.05 and a 200 day moving average price of $22.17. The company has a market cap of $1.25 billion, a P/E ratio of -10.52 and a beta of 1.89. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.90 and a quick ratio of 1.73. Myriad Genetics has a 12 month low of $12.87 and a 12 month high of $29.30.

Analyst Ratings Changes

MYGN has been the subject of several recent analyst reports. Bank of America decreased their price objective on shares of Myriad Genetics from $15.00 to $13.00 and set an “underperform” rating for the company in a report on Friday, December 13th. Leerink Partnrs cut Myriad Genetics from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 9th. Piper Sandler dropped their price objective on Myriad Genetics from $30.00 to $24.00 and set a “neutral” rating on the stock in a research note on Monday, November 11th. StockNews.com raised Myriad Genetics from a “hold” rating to a “buy” rating in a research note on Thursday, January 9th. Finally, UBS Group began coverage on Myriad Genetics in a report on Tuesday, December 10th. They set a “neutral” rating and a $18.00 target price on the stock. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $24.27.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.